Detrás de los titulares sobre el cáncer

Tema: Repercusiones de las nuevas leyes sobre el tratamiento contra el cáncer durante el embarazo

The U.S. Supreme Court ruled in 2022 that abortion is no longer a protected right under the Constitution.  This landmark decision leaves regulation of abortion to the states. Cancer treatment during pregnancy may now be impacted in states that have abortion bans or limitations. (Posted 5/31/23)

Este artículo está disponible en español.

Artículo: La decisión de una amante de la comida de extirparse el estómago pone en el reflector las difíciles decisiones en torno al riesgo de padecer cáncer

National Public Radio reporter Sáša Woodruff shares her story of learning about her CDH1 mutation and making a decision about risk-reducing surgery. Mutations in the CDH1 gene significantly increase a person’s risk of stomach and breast cancers. Woodruff’s personal essay describes the psychological challenge of making decisions about risk-reducing surgeries and draws attention to a lesser-known mutation linked to hereditary cancer. (Posted 5/17/23)

Este artículo está disponible en español.

Estudio: Los resultados del cáncer de mama mejoraron con un tratamiento específico

A study showed that people with metastatic breast cancer who took an oral drug known as a CDK4/6 inhibitor combined with hormone therapy did better than people who took hormone therapy alone. The drug combination improved the length of time before cancer worsened or returned. After six years of treatment, people who took this drug combination lived longer compared to those who took hormone therapy alone. (Posted 4/5/23)

Este artículo está disponible en español.

Estudio: El peso puede afectar el riesgo de padecer cáncer de mama en las mujeres con una mutación hereditaria en el gen BRCA

A study that looked at normal breast cells from women with an inherited BRCA mutation found more DNA damage among women who were overweight (based on a measurement known as body mass index) than those who were not overweight. The results suggest that maintaining a lower weight may reduce breast cancer among this high-risk population. (Posted 3/30/23)

Este artículo está disponible en español.

Estudio: Nuevo tratamiento con un medicamento oral contra el cáncer de mama avanzado

The FDA has approved a new oral drug called Oserdu for the treatment of HR-positive, HER2-negative advanced breast cancer. A blood test was also approved to help doctors identify patients who would benefit most from this new treatment. (Posted 3/20/23)

Este artículo está disponible en español.

Estudio: El racismo sistémico puede retardar el procedimiento de biopsia de mama en las personas de raza negra y asiática

Black and Asian people are more likely to have to wait more than 90 days between an abnormal mammogram and a biopsy compared to white people. After accounting for other factors, the authors conclude that these disparities may be due to systemic racism. (Posted 3/8/23)

Este artículo está disponible en español.

Estudio: El tratamiento para reducir las fracturas óseas también mejora la supervivencia al cáncer de mama en personas posmenopáusicas

A large study looked at the effects of adding the bone-protective drug denosumab (Prolia), to standard hormone therapy for the treatment of early-stage, postmenopausal, HR-positive breast cancer. The researchers found that adding denosumab to aromatase inhibitor hormonal therapy improved bone health, disease-free survival and overall survival. (Posted 2/27/23)

Este artículo está disponible en español.

Estudio: Aumentar el consumo de soya en su dieta puede disminuir su riesgo de cáncer

This study looked at a link between a diet rich in soy and cancer risk. With the addition of more recent literature, this study suggests that soy lowers the risk of cancer in the general population. (Posted 2/24/23)

Este artículo está disponible en español.

Estudio: Trodelvy tiene resultados favorables en personas con cáncer de mama metastásico positivo al receptor hormonal

The study TROPiCS-2 showed that the drug Trodelvy (sacituzumab govitecan) improved progression-free survival when compared to chemotherapy in people with advanced metastatic ER/PR-positive, HER2-negative breast cancer who have few other treatment options. This drug does not yet have FDA approval for use in the hormone-positive setting. (Posted 1/18/23)

Update: On 02/03/2023 the FDA approved Trodelvy for patients with locally advanced or metastatic  breast cancer who have received hormonal therapy and at least two other types of treatment in the metastatic setting.

Este artículo está disponible en español.

Actualización: El estudio de la vacuna contra el cáncer de mama inicia con la participación de personas con mutaciones en los genes BRCA1 y PALB2

A new vaccine was first tested on people diagnosed with triple-negative breast cancer. The vaccine is now being tested to prevent breast cancer among people with an inherited mutation in BRCA1 or PALB2 who are at high risk and who are planning to have a risk-reducing mastectomy. (Posted 1/9/23) Este artículo está disponible en español.